Obermatt
See Similar Stocks →

Flags

Financial distress

Inotiv

NAQ:NOTV · US45783Q1004
Life Sciences Tools & ServicesSmall

360

16
Medium confidence — indicative
Profit price37
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit84
Price/Book100
Return on Capital44
Cash Return on Capital56
Return on Equity10
EBIT Margin43
Gross Profitability50
Accruals59
Owner Earnings Margin51
Sales growth30
Profit growth84
Reinvestment71
Price momentum1
Debt load10
Refinancing100
Debt Payback1
Liquidity80
Analyst ratings100
Expectations trend50
Market mood5
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Inotiv doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1974
Employees966
Websiteinotiv.com
ISINUS45783Q1004
Last UpdateApr 2, 2026
Index & Theme
Animal FeedLivestockHealth DiagnosticsPharmacovigilanceBiomedical EngineeringGeneticsOncologyBiopharmaLife ScienceMedical DevicePharmaceutical

Description

Inotiv, Inc. (‘Inotiv’), together with its subsidiaries, provides nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and die…

Analysis

Middle-of-the-road

Inotiv, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is mixed; the safety picture is fragile. The company scores 4/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
67
2023202420252026

All-time high

76

Mar 2026

All-time low

31

Jan 2025

Average rank

52

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
95
100
83
Price/Earnings
53
53
53
53
Price/Book
100
94
89
41
Dividend Yield
1
1
1
1
Value (overall)
92
85
88
67

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Inotiv with its peers
Charles River Laboratories
NYQ:CRL
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Pacific Biosciences of California
NSQ:PACB
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Gain Therapeutics
NMQ:GANX
59
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Schrödinger
NSQ:SDGR
14
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
Certara
NSQ:CERT
45
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
Aclaris Therapeutics
NSQ:ACRS
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →